Gilead Sciences
| Company type | Public |
|---|---|
| Industry | Biopharmaceuticals |
| Founded | June 1987 |
| Founder | Michael L. Riordan |
| Headquarters | Foster City, California , United States |
Area served | Worldwide |
Key people | Michael L. Riordan (founder) |
| Products | Antiviral medications including ledipasvir/sofosbuvir, sofosbuvir, Tamiflu, Vistide, Viread, Hepsera, Truvada, Atripla, Yescarta, Tecartus |
Number of employees | 350 (circa 1999) |
| Website | www |
Gilead Sciences, Inc. () is a U.S.-based biopharmaceutical enterprise located in Foster City, California, concentrating on antiviral medications aimed at treating conditions such as HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. Its product lineup features important drugs including ledipasvir/sofosbuvir and sofosbuvir. Gilead is publicly traded on the Nasdaq-100 and S&P 100 indexes.
Established in 1987 by Michael L. Riordan under the original name Oligogen, the company initially focused on oligonucleotide research targeting genetic material. The firm went public in 1992 and introduced notable pharmaceuticals like Tamiflu and Vistide during that period.
During the 2000s, Gilead broadened its pharmaceutical portfolio with the approval of medications such as Viread and Hepsera. Transitioning from a biotechnology emphasis, it evolved into a more comprehensive pharmaceutical organization through strategic acquisitions while continuing substantial contract manufacturing operations.
In the 2010s, Gilead aggressively expanded its commercial footprint but encountered criticism over the elevated drug prices in the U.S., particularly for products like Sovaldi and Truvada, when compared to production expenses and pricing in lower-income countries. This sparked debates regarding its corporate approach and market dominance.
Foundation
Gilead Sciences was launched in June 1987 under the name Oligogen by Michael L. Riordan, a physician and entrepreneur educated at Washington University in St. Louis, Johns Hopkins School of Medicine, and Harvard Business School. The company began as a research initiative within Menlo Ventures, where Riordan worked as an associate. He brought together a group of scientific consultants including Peter Dervan (Caltech), Doug Melton (Harvard), Harold Weintraub (Fred Hutchinson Cancer Research Center), alongside Menlo Ventures’ founder H. Dubose Montgomery. Riordan held the CEO position until 1996. Menlo Ventures provided an initial funding of $2 million.
The business model centered on antiviral drug development, motivated by Riordan’s own encounter with dengue fever. Early board members featured prominent figures such as Donald Rumsfeld, Benno C. Schmidt Sr., Gordon Moore, and George P. Shultz. Although Riordan attempted to enlist Warren Buffett’s involvement, this effort was unsuccessful.
Originally, the company concentrated on antisense technology—crafting short DNA sequences (oligonucleotides) aimed at specific gene targets. The transition to the name Gilead Sciences occurred after resolving trademark conflicts with a California nonprofit; the chosen name was inspired by Riordan’s interest in medical history and literature.
By 1988, Gilead had moved its main office to Foster City, California, where it continues to operate today. In 1991, the firm pivoted toward developing small molecule antivirals by acquiring licenses for nucleotide analogs such as tenofovir, which later became a foundational medication.
Riordan characterized the initial decade as exceptionally demanding, marked by an absence of products or income and several close calls with bankruptcy. Establishing a sustainable business framework and achieving revenue generation were critical objectives during these early years.
1990–1999: Initial Public Offering
In January 1992, Gilead went public on the NASDAQ, successfully raising $86.25 million through its initial public offering. Prior to this, the company divested its antisense intellectual property portfolio to Ionis Pharmaceuticals.
June 1996 saw the introduction of Vistide (cidofovir injection), a treatment aimed at combating cytomegalovirus (CMV) retinitis in patients with AIDS.
Donald Rumsfeld was named chairman in January 1997, a position he held until January 2001 before assuming the role of United States Secretary of Defense under President George W. Bush.
In March 1999, Gilead expanded by acquiring NeXstar Pharmaceuticals, based in Boulder, Colorado. NeXstar, with annual revenues of $130 million—three times that of Gilead—offered products such as AmBisome, an injectable antifungal, and DaunoXome, an oncology medication for HIV patients. That same year, Roche obtained FDA approval for Tamiflu (oseltamivir) as an influenza treatment. Tamiflu had originally been discovered by Gilead and was licensed to Roche for advanced development and commercialization.
At this stage, Gilead employed only 350 people and lacked an international sales network. To retain control over future global marketing efforts and avoid licensing agreements, the company acquired NeXstar, which possessed an established European sales team promoting AmBisome.
2000 to 2009
Viread (tenofovir) gained its initial FDA approval in 2001 for the treatment of HIV.
In 2002, Gilead realigned its corporate focus exclusively toward antiviral therapies, selling off its oncology assets to OSI Pharmaceuticals for $200 million. Later that December, Gilead purchased Triangle Pharmaceuticals for approximately $464 million, acquiring emtricitabine near FDA approval alongside two additional antiviral candidates in development. This year also marked Gilead’s first full year generating profits. Hepsera (adefovir) received approval for chronic hepatitis B treatment, while Emtriva (emtricitabine) was authorized for HIV therapy.
By 2003, Gilead had transformed from a biotechnology startup into a pharmaceutical firm with an expanding headquarters campus in Foster City, which it fully acquired in 2004 for $123 million. Despite growth in sales and distribution infrastructure, Gilead continued to rely extensively on contract manufacturing organizations (CMOs) to maintain production flexibility.
During the 2004 Avian flu outbreak concerns, Tamiflu sales surged to $44.6 million as over 60 governments stockpiled the antiviral medication. Sales nearly quadrupled again in 2005 to $161.6 million, significantly elevating share prices. Notably, Donald Rumsfeld, then serving as Defense Secretary, earned over $5 million from his holdings in Gilead during this period.
In 2006, Gilead entered the respiratory therapeutics market by acquiring Corus Pharma for $365 million; this acquisition included aztreonam lysine designed for cystic fibrosis patients infected with Pseudomonas aeruginosa. The FDA approved Atripla—a once-daily single-tablet HIV treatment combining medications from both Gilead and Bristol-Myers Squibb—in July 2006.
Later that year, the company bolstered its active pharmaceutical ingredient manufacturing by acquiring Raylo Chemicals for $133.3 million. Additionally, Gilead completed its largest acquisition at the time by purchasing Myogen for $2.5 billion, enhancing its pulmonary disease portfolio with marketed drug Flolan and pipeline candidates ambrisentan and darusentan.
In 2007, Gilead expanded respiratory drug development through a licensing agreement with Parion Sciences for an epithelial sodium channel inhibitor targeting pulmonary conditions such as cystic fibrosis and COPD.
The acquisition of CV Therapeutics in 2009 for $1.4 billion brought cardiovascular drugs Ranexa and Lexiscan into Gilead’s product lineup, strengthening its cardiovascular franchise. That same year, Fortune acknowledged Gilead as one of the Fastest Growing Companies in recognition of its robust business expansion and market presence.
2010 to 2019
In 2010, Gilead expanded its kinase biology and chemistry research by acquiring CGI Pharmaceuticals for $120 million. Later that year, it enhanced its portfolio with the $225 million purchase of Arresto Biosciences, which brought in developmental candidates targeting fibrotic diseases and cancer.
February 2011 saw Gilead strengthen its oncology and inflammation pipeline through the $375 million acquisition of Calistoga Pharmaceuticals. That same year, Gilead made a transformative move by acquiring Pharmasset for $10.4 billion, securing the hepatitis C drug sofosbuvir and cementing its position as a leader in antiviral therapies.
In October 2011, Gilead undertook a significant expansion of its Foster City campus, nearly doubling its office space to approximately 1.2 million square feet.
The FDA’s July 2012 approval of Truvada for pre-exposure prophylaxis (PrEP) broadened the drug’s application from HIV treatment to prevention in high-risk populations.
In 2013, the acquisition of YM Biosciences for $510 million added CYT387, a selective Janus kinase inhibitor focused on myeloproliferative disorders and certain cancers, bolstering Gilead’s oncology pipeline.
During 2015, Gilead completed three key acquisitions: Phenex Pharmaceuticals for $470 million to advance FXR agonists targeting liver conditions; EpiTherapeutics for $65 million to gain access to histone demethylase inhibitors in oncology; and a 15% equity investment in Galapagos NV for $425 million, securing rights to filgotinib, an anti-inflammatory candidate.
In 2016, Gilead purchased Nimbus Apollo for $400 million, acquiring ACC inhibitors aimed at treating non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma. That year also highlighted Gilead’s philanthropic efforts as it was recognized as the most generous company on the Fortune 500 list, donating over $440 million toward HIV/AIDS and liver disease initiatives.
August 2017 marked a strategic milestone with the $11.9 billion acquisition of Kite Pharma, enabling Gilead’s entry into the cell therapy arena with CAR-T treatments. This acquisition expanded its oncology portfolio with products such as Yescarta and Tecartus by 2022. Later in 2017, Gilead announced plans to acquire Cell Design Labs for up to $567 million, further enhancing its cell therapy capabilities.
On May 9, 2019, Gilead pledged to supply Truvada at no cost to 200,000 patients annually over an 11-year period through collaboration with the U.S. Department of Health and Human Services (HHS). By December that year, HHS outlined distribution strategies and agreed to reimburse Gilead $200 per bottle for logistics expenses.
2020 onwards
In March 2020, Gilead announced its intent to acquire Forty Seven Inc. at $95.50 per share in a deal valued around $4.9 billion, finalizing the acquisition in April and broadening its oncology portfolio.
June 2020 saw AstraZeneca reportedly propose a preliminary merger offer worth approximately $240 billion to Gilead. In the same month, Gilead acquired a 49.9% stake in Pionyr Immunotherapeutics Inc for $275 million, augmenting its cancer drug development pipeline.
In September 2020, Gilead agreed to purchase Immunomedics for $21 billion ($88 per share), gaining control over Trodelvy (Sacituzumab govitecan-hziy), an innovative Trop-2 antibody-drug conjugate used in cancer treatment. By December, it announced the €1.15 billion acquisition of German biotech MYR GmbH, specializing in therapies against chronic hepatitis delta virus.
In August 2021, U.S. Senator Rand Paul disclosed that his spouse had acquired shares in Gilead during early 2020.
By November 2021, Gilead was included in the Dow Jones Sustainability World Index, recognizing its dedication to sustainable business practices.
In January 2022, Gilead voluntarily withdrew Zydelig (idelalisib) from accelerated approval for certain lymphoma indications. Later that year in September, it completed the $405 million purchase of MiroBio, expanding its immuno-oncology assets.
February 2023 brought the completion of Tmunity Therapeutics’ acquisition through subsidiary Kite Pharma. In May, Gilead acquired XinThera along with its small molecule inhibitors to reinforce early-stage oncology and inflammation research efforts.
In February 2024, Gilead acquired CymaBay Therapeutics and subsequently invested $35 million in Genesis Therapeutics in September to enhance AI-driven drug discovery capabilities.
By May 2025, Gilead committed $10 million to secure exclusive rights over arenavirus immunotherapies targeting hepatitis B (HBV) and HIV from its collaboration with Hookipa Pharma, demonstrating a strategic emphasis on viral disease therapeutics.
Acquisition history
- Gilead Sciences
- NeXstar Pharmaceuticals (Acquired 1999)
- Triangle Pharmaceuticals (Acquired 2003)
- Myogen, Inc. (Acquired 2006)
- Corus Pharma, Inc (Acquired 2006)
- Raylo Chemicals (Acquired 2006)
- CV Therapeutics, Inc. (Acquired 2009)
- CGI Pharmaceuticals (Acquired 2010)
- Calistoga Pharmaceuticals (Acquired 2011)
- Pharmasset Inc (Acquired 2011)
- Phenex Pharmaceuticals (Acquired 2015)
- EpiTherapeutics (Acquired 2015)
- Galapagos NV (Acquired 2015)
- Nimbus Apollo, Inc. (Acquired 2016)
- Kite Pharma (Acquired 2017)
- Cell Design Labs (Acquired 2017)
- Tmunity Therapeutics (Acquired 2023)
- Forty Seven (Acquired 2020)
- Immunomedics (Acquired 2020)
- MYR GmbH (Acquired 2020)
- MiroBio (Acquired 2022)
- CymaBay Therapeutics (Acquired 2024)
Treatments for hepatitis C
Sofosbuvir, obtained through the $11 billion acquisition of Pharmasset in 2011, received FDA approval in 2013 under the brand name Sovaldi for hepatitis C therapy. Forbes ranked Gilead as the fourth leading pharmaceutical company, citing this acquisition as a pivotal factor in achieving a market capitalization of $113 billion and notable stock appreciation. Deutsche Bank forecasted $53 million in fourth-quarter sales for Sovaldi, while Barron's emphasized its favorable influence on the company's financial outcomes.
In 2014, members of the U.S. Senate Finance Committee raised concerns regarding Sovaldi's $1,000 per pill cost, leading CEO John C. Martin to defend the pricing strategy amidst debates over market fairness. Although no new legislation followed, subsequent negotiations resulted in price reductions. To increase access globally and capture market share in developing nations, Gilead authorized generic manufacturing in India, lowering prices to approximately $4.29 per pill.
Gilead expanded its hepatitis C treatment lineup by developing single-tablet regimens combining Sovaldi with other antiviral agents, such as Harvoni (which includes ledipasvir), yielding cure rates between 94% and 99% for patients with genotype 1. Nonetheless, by 2017, revenues from Sovaldi declined significantly due to competitive pricing pressures and a diminishing patient base. Additional combination therapies launched included Epclusa (with velpatasvir) and Vosevi (incorporating velpatasvir and voxilaprevir), underscoring Gilead's strategic role in broadening hepatitis C treatment options.
Finances
For the fiscal year ending in 2017, Gilead Sciences reported net earnings of $4.628 billion alongside revenues totaling $26.107 billion, representing a decrease of 14.1% compared to the previous year. By October 2018, its stock price exceeded $70 per share, corresponding to a market value of $93.4 billion.
| Year | Revenue in million USD$ |
Net income in million USD$ |
Total assets in million USD$ |
Price per share in USD$ |
Employees | |
|---|---|---|---|---|---|---|
| 2005 | 2,028 | 814 | 3,766 | 9.77 | ||
| 2006 | 3,026 | −1,190 | 4,086 | 14.31 | ||
| 2007 | 4,230 | 1,585 | 5,835 | 18.30 | ||
| 2008 | 5,336 | 1,979 | 6,937 | 22.74 | ||
| 2009 | 7,011 | 2,636 | 9,699 | 21.32 | ||
| 2010 | 7,949 | 2,901 | 11,593 | 18.15 | ||
| 2011 | 8,385 | 2,804 | 17,303 | 18.46 | ||
| 2012 | 9,702 | 2,592 | 21,240 | 26.13 | ||
| 2013 | 11,202 | 3,075 | 22,579 | 51.83 | 6,000 | |
| 2014 | 24,890 | 12,101 | 34,664 | 82.82 | 7,000 | |
| 2015 | 32,639 | 18,108 | 51,716 | 98.83 | 8,000 | |
| 2016 | 30,390 | 13,501 | 56,977 | 78.87 | 9,000 | |
| 2017 | 26,107 | 4,628 | 70,283 | 70.13 | 10,000 | |
| 2018 | 22,127 | 5,455 | 63,675 | 63.86 | 11,000 | |
| 2019 | 22,449 | 5,386 | 61,627 | 11,800 | ||
| 2020 | 24,689 | 123 | 68,407 | 13,600 | ||
| 2021 | 27,305 | 6,225 | 67,952 | 14,400 |
This financial summary illustrates Gilead's revenue variations and employee growth consistent with its strategic development and expanding footprint within the pharmaceutical sector.
Future Outlook
By 2017, Gilead’s primary objective was to either develop or acquire new blockbuster medications before the decline or patent expiration of its existing revenue-generating products. The company gained advantages from Medicaid expansion under the Affordable Care Act, although its HIV treatment portfolio could encounter funding constraints amid proposed healthcare reforms. Gilead possessed $32 billion in cash reserves, with $27.4 billion held overseas, which restricts acquisition opportunities without triggering U.S. tax liabilities; however, leveraging these offshore funds through borrowing remains feasible. Legislative proposals permitting the repatriation of foreign-held capital with minimal taxation could significantly improve Gilead’s capacity for acquisitions.
Among its development pipeline is Entospletinib, which has shown a 90% complete response rate in treating MLL-type acute myeloid leukemia (AML), indicating promising prospects for growth within the oncology sector.
Delays in TAF Development
Gilead has been subject to mass tort litigation accusing the company of intentionally postponing the advancement of tenofovir alafenamide fumarate (TAF) to prolong profits from older tenofovir disoproxil fumarate (TDF) products. Plaintiffs argue that Gilead halted TAF development as early as 2004 despite evidence suggesting that TAF-based therapies offered improved safety profiles compared to TDF, which has been associated with adverse effects such as nephrotoxicity and reductions in bone density.
The company introduced its initial TAF-based drug, Genvoya, in 2015. The lawsuits claim that during the delay period, numerous HIV patients treated with TDF experienced serious side effects, thereby damaging Gilead’s reputation and raising concerns regarding its strategic decision-making and corporate ethics.
Biktarvy
In 2023, the Institute for Clinical and Economic Review (ICER) identified Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) among five costly pharmaceuticals that experienced substantial net price increases without corresponding new clinical benefits. The wholesale acquisition cost of Biktarvy rose by 5.49%, resulting in an additional $815 million burden on U.S. healthcare payers.
Sovaldi
Gilead encountered significant backlash over the pricing of sofosbuvir (Sovaldi), its patented hepatitis C medication. Upon release in the United States, Sovaldi was priced at approximately $1,000 per pill or $84,000 for a typical treatment course, whereas in developing nations like India, the price was dramatically lower—around $4.29 per pill. Despite representing a major therapeutic advancement, Sovaldi’s cost ignited widespread debate regarding drug affordability and equitable pricing practices.
An 18-month investigation by the U.S. Senate Committee on Finance scrutinized Gilead’s pricing approach and concluded that prices were strategically set high to maximize profits and pave the way for Sovaldi’s successor, Harvoni, with limited consideration given to research and development expenses. Internal documents revealed that Gilead evaluated annual prices ranging from $50,000 to $115,000 to balance revenue objectives against potential public criticism.
The elevated costs compelled state Medicaid programs to limit patient access. For instance, Oregon restricted Sovaldi treatment to 500 patients annually out of approximately 10,000 eligible individuals because treating half of those candidates would more than double the state’s pharmaceutical spending.
Truvada and Descovy
Truvada, introduced by Gilead in 2004 for HIV therapy, later became widely recognized for its role in preventing HIV transmission. The US Centers for Disease Control holds the patent for its application as pre-exposure prophylaxis (PrEP). In 2012, Gilead launched Truvada specifically for PrEP use, with a US price tag near $1,200 monthly, which escalated to almost $2,000 by 2018, despite its international cost being below $100. By 2018, Truvada’s sales surpassed $3 billion, highlighting its dominant position in the market.
The elevated pricing drew significant backlash from advocacy groups and prompted a Congressional hearing in 2019. Gilead’s CEO defended the pricing strategy by emphasizing the company’s extensive investment in HIV/AIDS research initiatives. Meanwhile, activists called for government intervention to enforce patent regulations and counteract Gilead’s pricing policies.
In May 2019, after discussions with the Department of Health and Human Services, Gilead pledged to donate enough Truvada to treat up to 200,000 patients annually over an 11-year span. Experts pointed out this donation would cover less than 20% of those requiring treatment and suggested it was a calculated effort to encourage uptake of Descovy, which succeeded Truvada. A 2020 analysis led by Dr. Rochelle Walensky found that Descovy’s higher price reduced its cost-effectiveness relative to generic Truvada.
In July 2021, Gilead cut reimbursements under the 340B Drug Pricing Program for clinics serving economically disadvantaged populations. This move was criticized for potentially restricting access to HIV/AIDS prevention and treatment among vulnerable groups.
Anticompetitive behavior
Gilead has been accused of impeding market competition through "pay-for-delay" arrangements that deferred the availability of generic Truvada versions. Legal actions initiated in the US during 2019 and 2021 by pharmaceutical manufacturers and pharmacy chains such as CVS and RiteAid alleged that Gilead and other drug companies obstructed lower-cost generics to maintain market dominance.
Following criticism over Sovaldi’s pricing, Gilead licensed generic manufacturing rights to certain Indian producers in 2015. These agreements included 'anti-diversion' provisions designed to prevent cheaper medications from re-entering developed markets. The licensing process involved patient screening requirements that attracted criticism for possibly excluding at-risk populations. Subsequently, Gilead relaxed these conditions to enhance drug accessibility.
Tax structures and tax avoidance
Gilead has faced scrutiny for employing legal tax avoidance mechanisms that transfer profits to jurisdictions with lower tax rates, thereby minimizing its overall tax liabilities despite substantial revenues in higher-tax countries. A 2016 investigation estimated that Gilead avoided up to $10 billion in US taxes through strategies such as transfer pricing and internal asset transfers—most notably by selling intellectual property rights to an Irish subsidiary responsible for distributing products like Sovaldi.
Such practices are typical among multinational pharmaceutical corporations seeking favorable tax positions. Reports from 2018 indicated that Gilead utilized the "Double Irish" tax scheme to shift nearly €20 billion in profits through Ireland without incurring local taxes. Following reforms in US corporate taxation, Gilead repatriated $28 billion from its Irish subsidiary and paid approximately $5.5 billion in taxes.
Remdesivir
On March 23, 2020, Gilead secured orphan drug status for remdesivir from the US FDA, providing extended market exclusivity along with exemptions from certain taxes and fees to promote development for illnesses affecting fewer than 200,000 individuals in the United States. At that point, remdesivir emerged as a prominent treatment candidate amid rapidly escalating COVID-19 cases across the country. Gilead possesses 20-year patent protections for remdesivir spanning more than 70 nations.
In 2021, remdesivir, marketed under the brand name Veklury, generated revenues exceeding $4.5 billion, establishing it as Gilead’s leading product in sales.
COVID-19
The United States authorized emergency use of remdesivir on May 1, 2020, specifically for patients hospitalized with severe COVID-19 symptoms. While the World Health Organization initially advised against its use in September 2020 due to insufficient evidence supporting its efficacy, later clinical studies prompted regulatory approvals for treating hospitalized COVID-19 patients in regions including the US, European Union, and Canada. A clinical trial conducted in Canada in 2022 demonstrated that remdesivir lowered mortality rates by approximately 4% and reduced the necessity for oxygen therapy and mechanical ventilation when compared with standard treatment protocols.
Regulatory approval
In October 2020, the FDA granted full approval to Veklury for managing severe COVID-19 cases in hospitalized adults and pediatric patients aged 12 years and older. Subsequently, in January 2022, the FDA broadened this approval to encompass adults and children (aged 12 years and above, weighing at least 40 kilograms) experiencing mild to moderate COVID-19 who are at elevated risk of progressing to severe illness, including hospitalization or death. Additionally, the FDA issued Emergency Use Authorization for Veklury in children under 12 years old with mild to moderate COVID-19 who face a high risk of severe disease outcomes.